Literature DB >> 11133631

Patient-controlled interscalene analgesia with ropivacaine 0.2% versus bupivacaine 0.15% after major open shoulder surgery: the effects on hand motor function.

A Borgeat1, F Kalberer, H Jacob, Y A Ruetsch, C Gerber.   

Abstract

UNLABELLED: We compared the effects of patient-controlled interscalene analgesia with ropivacaine 0.2% and patient-controlled interscalene analgesia (PCIA) with bupivacaine 0.15% on hand grip strength after major open shoulder surgery. Sixty patients scheduled for elective major shoulder surgery were prospectively randomized to receive in a double-blinded fashion either ropivacaine or bupivacaine through an interscalene catheter. Before surgery, all patients received an interscalene block (ISB) with either 40 mL of 0.6% ropivacaine or 40 mL of 0.5% bupivacaine. Six h after ISB, the patients received a continuous infusion of either 0.2% ropivacaine or 0.15% bupivacaine for 48 h. In both groups, the PCIA infusion rate was 5 mL/h plus a bolus of 4 mL with a lockout time of 20 min. Strength in the hand was assessed preoperatively, 24 h, and 48 h after ISB and 6 h after stopping the infusion of local anesthetic. The presence of paresthesia in the fingers was checked. Pain relief was assessed using a visual analog scale; side effects were noted, and the patients rated their satisfaction 54 h after the block. A significant decrease of strength in the hand was observed in the Bupivacaine group 24, 48, and 54 h after ISB (P < 0.05). Paresthesia was more frequently reported in the Bupivacaine group for the second and third fingers 48 h after ISB (P < 0.05) and in the first three fingers 6 h after discontinuation of the local anesthetic infusion (P: < 0.05). The pain score was similar in the two groups at all times, and patient satisfaction was comparable between the two groups. We conclude that the use of the PCIA technique with ropivacaine 0.2% or bupivacaine 0.15% provides a similar pain relief after major shoulder surgery. However, ropivacaine 0.2% is associated with better preservation of strength in the hand and less paresthesia in the fingers. IMPLICATIONS: We compared the patient-controlled interscalene analgesia technique with ropivacaine 0.2% and bupivacaine 0.15% after major open shoulder surgery. For similar pain control ropivacaine is associated with better preservation of strength in the hand and less paresthesia in the fingers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11133631     DOI: 10.1097/00000539-200101000-00042

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  20 in total

1.  Continuous femoral nerve blocks: decreasing local anesthetic concentration to minimize quadriceps femoris weakness.

Authors:  Maria Bauer; Lu Wang; Olusegun K Onibonoje; Chad Parrett; Daniel I Sessler; Loran Mounir-Soliman; Sherif Zaky; Viktor Krebs; Leonard T Buller; Michael C Donohue; Jennifer E Stevens-Lapsley; Brian M Ilfeld
Journal:  Anesthesiology       Date:  2012-03       Impact factor: 7.892

Review 2.  Ropivacaine: a review of its use in regional anaesthesia and acute pain management.

Authors:  Dene Simpson; Monique P Curran; Vicki Oldfield; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Effects of local anesthetic concentration and dose on continuous interscalene nerve blocks: a dual-center, randomized, observer-masked, controlled study.

Authors:  Linda T Le; Vanessa J Loland; Edward R Mariano; J C Gerancher; Anupama N Wadhwa; Elizabeth M Renehan; Daniel I Sessler; Jonathan J Shuster; Douglas W Theriaque; Rosalita C Maldonado; Brian M Ilfeld
Journal:  Reg Anesth Pain Med       Date:  2008 Nov-Dec       Impact factor: 6.288

Review 4.  Upper extremity regional anesthesia: essentials of our current understanding, 2008.

Authors:  Joseph M Neal; J C Gerancher; James R Hebl; Brian M Ilfeld; Colin J L McCartney; Carlo D Franco; Quinn H Hogan
Journal:  Reg Anesth Pain Med       Date:  2009 Mar-Apr       Impact factor: 6.288

5.  Randomized, controlled trial of multimodal shoulder injection or intravenous patient-controlled analgesia after arthroscopic rotator cuff repair.

Authors:  Sun Sook Han; Ye Hyun Lee; Joo Han Oh; Susan Aminzai; Sae Hoon Kim
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2012-09-19       Impact factor: 4.342

6.  [Ropivacain after inguinal hernia surgery. A prospective, randomised, double-blinded, controlled study].

Authors:  C Peiper; P Ehrenstein; D Schubert; K Junge; C Krones; V Schumpelick
Journal:  Chirurg       Date:  2005-05       Impact factor: 0.955

7.  The association between lower extremity continuous peripheral nerve blocks and patient falls after knee and hip arthroplasty.

Authors:  Brian M Ilfeld; Kimberly B Duke; Michael C Donohue
Journal:  Anesth Analg       Date:  2010-10-01       Impact factor: 5.108

8.  Continuous femoral nerve blocks: varying local anesthetic delivery method (bolus versus basal) to minimize quadriceps motor block while maintaining sensory block.

Authors:  Matthew T Charous; Sarah J Madison; Preetham J Suresh; NavParkash S Sandhu; Vanessa J Loland; Edward R Mariano; Michael C Donohue; Pascual H Dutton; Eliza J Ferguson; Brian M Ilfeld
Journal:  Anesthesiology       Date:  2011-10       Impact factor: 7.892

9.  A clinical comparison of continuous interscalene brachial plexus block with different basal infusion rates of 0.2% ropivacaine for shoulder surgery.

Authors:  Chun Woo Yang; Sung Mee Jung; Hee Uk Kwon; Choon-Kyu Cho; Jin Woong Yi; Chul Woung Kim; Jong-Kwon Jung; Young Mi An
Journal:  Korean J Anesthesiol       Date:  2010-07-21

10.  Ambulatory continuous femoral nerve blocks decrease time to discharge readiness after tricompartment total knee arthroplasty: a randomized, triple-masked, placebo-controlled study.

Authors:  Brian M Ilfeld; Linda T Le; R Scott Meyer; Edward R Mariano; Krista Vandenborne; Pamela W Duncan; Daniel I Sessler; F Kayser Enneking; Jonathan J Shuster; Douglas W Theriaque; Linda F Berry; Eugene H Spadoni; Peter F Gearen
Journal:  Anesthesiology       Date:  2008-04       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.